Teligent Net Change in Intangible Assets 2010-2021 | TLGT

Teligent net change in intangible assets from 2010 to 2021. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
Teligent Annual Net Change in Intangible Assets
(Millions of US $)
2020 $N/A
2019 $N/A
2018 $N/A
2017 $N/A
2016 $N/A
2015 $-35
2014 $N/A
2013 $N/A
2012 $N/A
2011 $N/A
2010 $N/A
2009 $N/A
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.000B $0.000B
Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $21.563B 7.52
Dr Reddy's Laboratories (RDY) India $12.039B 21.85
BridgeBio Pharma (BBIO) United States $9.602B 0.00
Bausch Health Cos (BHC) Canada $2.776B 1.99
Supernus Pharmaceuticals (SUPN) United States $2.429B 16.53
Amphastar Pharmaceuticals (AMPH) United States $1.379B 9.69
Taysha Gene Therapies (TSHA) United States $0.783B 0.00
Personalis (PSNL) United States $0.413B 0.00
Assembly Biosciences (ASMB) United States $0.204B 0.00
Sol-Gel Technologies (SLGL) Israel $0.072B 0.00
Evoke Pharma (EVOK) United States $0.010B 0.00